StreetInsider.com News Articles

Leerink Partners Reiterates Outperform Rating on BridgeBio Pharma (BBIO) after data presentation: "risk/reward skewed to the upside"

Thu, 12 Mar 2026 09:24:45 -0400

Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $98.00 price target on BridgeBio Pharma (NASDAQ: BBIO)

The analyst commented, "The presentation is a net positive, albeit largely incremental – early 3-month 100MTT separation, granular CK normalization, and traditional approval path confirmation are the key additions. The LGMD2I/R9 opportunity remains a point of disconnect for the Street: we see a first-in-disease agent in a high unmet need indication, with a clean safety profile with a long lead-time to launch vs gene therapy alternatives still years away – a setup for a strong launch to establish a durable position as standard-of-care.

BridgeBio reports positive phase 3 results for LGMD2I/R9 drug BBP-418

Wed, 11 Mar 2026 14:00:16 -0400

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported positive interim results from its phase 3 FORTIFY trial of BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The data were presented at the MDA Clinical and Scientific Conference.

The study showed BBP-418 demonstrated early separation from placebo on the 100-meter timed test, with improvements in ambulation evident at three months. At 12 months, patients treated with BBP-418 completed the test approximately 31 seconds faster than those receiving placebo.

Treatment resulted in sustained reduction in serum creatine kinase levels, with 59.6% of patients achieving levels within twice the upper limit of normal and

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Wed, 11 Mar 2026 14:00:00 -0400

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups

- Early separation from placebo observed in 100MTT, with improvements in ambulation evident as early as three months following initiation of BBP-418 treatment

- Based on the positive interim analysis results, BridgeBio intends to submit an NDA to the FDA for traditional approval in the first half of 2026 with a U.S. launch anticipated in late 2026/early 2027

- If successful, BBP-418 could be the first approved therapy

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Wed, 11 Mar 2026 14:00:00 -0400

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups

- Early separation from placebo observed in 100MTT, with improvements in ambulation evident as early as three months following initiation of BBP-418 treatment

- Based on the positive interim analysis results, BridgeBio intends to submit an NDA to the FDA for traditional approval in the first half of 2026 with a U.S. launch anticipated in late 2026/early 2027

- If successful, BBP-418 could be the first approved therapy

Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah

Tue, 10 Mar 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260310/26139200.html

Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah

Tue, 10 Mar 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260310/26139200.html

Barclays Reiterates Overweight Rating on BridgeBio Pharma (BBIO) amid tafamidis IP trial update

Tue, 10 Mar 2026 12:42:40 -0400

Barclays analyst Eliana Merle reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ: BBIO)
The analyst commented, "On Tuesday 3/10, the judge in the PFE (covered by Emily Field) US tafamidis IP trial issued a memorandum opinion denying the ANDA filers' motion to exclude PFE expert testimony. We note from our prior work on taf IP, including a legal expert call (link) that the admissibility of PFE's expert testimony was flagged as a key swing factor in the case; the outcome now appears to be in PFE's favor in allowing the testimony (both Matzger's curve fitting & Raman

BridgeBio Pharma (BBIO) PT Raised to $94 at JPMorgan

Tue, 10 Mar 2026 07:58:15 -0400
JPMorgan analyst Anupam Rama raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $94.00 (from $89.00) while maintaining a Overweight rating.

William Blair Starts BridgeBio Pharma (BBIO) at Outperform

Tue, 10 Mar 2026 06:34:51 -0400

William Blair analyst John Boyle initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating.
The analyst comments "We are initiating coverage of BridgeBio Therapeutics with an Outperform rating and fair value of $93.03 per share. BridgeBio is a commercial-stage biotech company in a unique position with an accelerating launch in Attruby, near-term NDA submissions for disease-modifying therapies (encaleret in ADH1 and BBP-418 in LGMD2I/R9) setting up late-2026/early-2027 launches, and regulatory submission for infigratinib in achondroplasia planned for second half 2026. Attruby is well positioned for growth in ATTR-CM. Attruby (a second-generation stabilizer) is launching alongside Alnylam’s Amvuttra (a silencer)

William Blair Starts BridgeBio Pharma (BBIO) at Outperform

Tue, 10 Mar 2026 06:34:51 -0400

William Blair analyst John Boyle initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating.
The analyst comments "We are initiating coverage of BridgeBio Therapeutics with an Outperform rating and fair value of $93.03 per share. BridgeBio is a commercial-stage biotech company in a unique position with an accelerating launch in Attruby, near-term NDA submissions for disease-modifying therapies (encaleret in ADH1 and BBP-418 in LGMD2I/R9) setting up late-2026/early-2027 launches, and regulatory submission for infigratinib in achondroplasia planned for second half 2026. Attruby is well positioned for growth in ATTR-CM. Attruby (a second-generation stabilizer) is launching alongside Alnylam’s Amvuttra (a silencer)

Form 4 BridgeBio Pharma, Inc. For: Mar 04 Filed by: Ellis Andrea

Fri, 06 Mar 2026 16:58:00 -0400
si-local-file:///var/storage/secattach/20260306/26126381.html

Form 4 BridgeBio Pharma, Inc. For: Mar 04 Filed by: Ellis Andrea

Fri, 06 Mar 2026 16:58:00 -0400
si-local-file:///var/storage/secattach/20260306/26126381.html

Form 144 BridgeBio Pharma, Inc. Filed by: Ellis Andrea

Wed, 04 Mar 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260304/26111421.html

Form 144 BridgeBio Pharma, Inc. Filed by: Ellis Andrea

Wed, 04 Mar 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260304/26111421.html

BridgeBio to present FORTIFY trial data at MDA conference

Wed, 04 Mar 2026 07:30:44 -0400

BridgeBio Pharma Inc. (NASDAQ: BBIO) will present additional data from its Phase 3 FORTIFY trial at the MDA Clinical & Scientific Conference in Orlando, Florida from March 8-11, 2026, according to a company statement.

The FORTIFY trial evaluates BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Katherine Mathews, a professor at the University of Iowa's Roy J. and Lucille A. Carver College of Medicine, will deliver a late-breaking oral presentation titled "Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints" on March 11 at 2:00 pm ET.

Academic collaborators from Yale School

BridgeBio to present FORTIFY trial data at MDA conference

Wed, 04 Mar 2026 07:30:44 -0400

BridgeBio Pharma Inc. (NASDAQ: BBIO) will present additional data from its Phase 3 FORTIFY trial at the MDA Clinical & Scientific Conference in Orlando, Florida from March 8-11, 2026, according to a company statement.

The FORTIFY trial evaluates BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Katherine Mathews, a professor at the University of Iowa's Roy J. and Lucille A. Carver College of Medicine, will deliver a late-breaking oral presentation titled "Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints" on March 11 at 2:00 pm ET.

Academic collaborators from Yale School

BridgeBio to present FORTIFY trial data at MDA conference

Wed, 04 Mar 2026 07:30:11 -0400

BridgeBio Pharma, Inc. (NASDAQ: BBIO) will present additional data from the interim analysis of its Phase 3 FORTIFY clinical trial at the MDA Clinical & Scientific Conference in Orlando, Florida on March 8-11, 2026, according to a company statement.

The FORTIFY trial evaluates BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The data will be shared in a late-breaking oral presentation titled "Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints" on March 11 at 2:00 pm ET.

Katherine Mathews, M.D., Professor of Pediatrics and Neurology at the University of Iowa's Roy

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Wed, 04 Mar 2026 07:30:00 -0400

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Wed, 04 Mar 2026 07:30:00 -0400

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Wed, 04 Mar 2026 07:30:00 -0400

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Wed, 04 Mar 2026 07:30:00 -0400

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Wed, 04 Mar 2026 07:30:00 -0400

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Wed, 04 Mar 2026 07:30:00 -0400

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight

Form 4 BridgeBio Pharma, Inc. For: Feb 27 Filed by: Valantine Hannah

Tue, 03 Mar 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260303/26101775.html

Form 4 BridgeBio Pharma, Inc. For: Feb 27 Filed by: Valantine Hannah

Tue, 03 Mar 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260303/26101775.html